ProfileGDS5678 / 1429901_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 54% 54% 52% 53% 56% 58% 54% 53% 54% 54% 53% 54% 54% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4016254
GSM967853U87-EV human glioblastoma xenograft - Control 23.3303154
GSM967854U87-EV human glioblastoma xenograft - Control 33.3319254
GSM967855U87-EV human glioblastoma xenograft - Control 43.2105152
GSM967856U87-EV human glioblastoma xenograft - Control 53.250153
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5069956
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5818858
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3157454
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2689653
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3082654
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3288454
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.264353
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3542454
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3309754